Phreesia, Inc.

PHR

Held by 2 specialist biotech funds

Fund Holdings

Rock Springs Capital Deerfield Management

AI Signal

**Signal Note: Rock Springs Capital initiates $14.8M position in Phreesia (PHR)** Rock Springs' entry into PHR—a healthcare IT platform for patient intake and data management—signals confidence in the company's revenue trajectory and margin expansion potential, likely driven by increased software adoption post-pandemic normalization and potential M&A activity in the fragmented ambulatory EHR space.

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 876,600Value: $14.8M

Deerfield ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX2 funds MIRM2 funds NAMSW2 funds OMDA2 funds NUVB2 funds ALNY2 funds ACAD2 funds PHVS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Deerfield Management Initiates $33.8M Position in Phreesia (PHR)** Deerfield's new position signals conviction in PHR's healthcare IT platform amid accelerating digital health adoption and improving unit economics post-pandemic. The $33.8M stake represents a healthcare multi-strategy vote for the company's SaaS-based clinical workflow software, which has shown revenue growth but remains unprofitable—suggesting Deerfield sees a path to profitability or near-term margin expansion catalysts. The timing follows industry tailwinds in EHR interoperability and potential healthcare IT consolidation, though investors should monitor quarterly patient encounter trends as the primary revenue driver.